Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events - Additional Information (Detail) - License and Transfer Agreement [Member] - USD ($)		3 Months Ended
	Apr. 18, 2016	Mar. 31, 2016
Enumeral Biomedical Holdings Inc [Member]
Subsequent Event [Line Items]
Agreement termination description		The Enumeral Agreement may be terminated by the Company on 30 days' notice and by Enumeral upon 60 days' notice of a material breach by the Company (or 30 days with respect to a breach of payment obligations by the Company), provided that the Company has not cured such breach and dispute resolution procedures specified in the Enumeral Agreement have been followed.
Subsequent Event [Member]
Subsequent Event [Line Items]
Agreement termination notice period	30 days
Subsequent Event [Member] \| Enumeral Biomedical Holdings Inc [Member]
Subsequent Event [Line Items]
Upfront license fee payment	$ 250,000
Maintenance fee payment	$ 750,000
Agreement termination notice period upon material breach by the Company	60 days
Agreement termination notice period upon breach of payment obligations by the Company	30 days
Maximum [Member] \| Subsequent Event [Member] \| Enumeral Biomedical Holdings Inc [Member]
Subsequent Event [Line Items]
Development milestones payment	$ 37,800,000
Sales milestones payment	$ 67,500,000
Percentage of reduction in royalty payment	50.00%